DE69032841D1 - Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung - Google Patents

Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung

Info

Publication number
DE69032841D1
DE69032841D1 DE69032841T DE69032841T DE69032841D1 DE 69032841 D1 DE69032841 D1 DE 69032841D1 DE 69032841 T DE69032841 T DE 69032841T DE 69032841 T DE69032841 T DE 69032841T DE 69032841 D1 DE69032841 D1 DE 69032841D1
Authority
DE
Germany
Prior art keywords
host cell
hyperprolieferative
disorders
production
recombinant cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69032841T
Other languages
English (en)
Other versions
DE69032841T2 (de
Inventor
Mark Goldsmith
Robert Ralston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority claimed from PCT/US1990/000445 external-priority patent/WO1990007936A1/en
Application granted granted Critical
Publication of DE69032841D1 publication Critical patent/DE69032841D1/de
Publication of DE69032841T2 publication Critical patent/DE69032841T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69032841T 1989-01-23 1990-01-22 Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung Expired - Fee Related DE69032841T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30063789A 1989-01-23 1989-01-23
US46146190A 1990-01-17 1990-01-17
PCT/US1990/000445 WO1990007936A1 (en) 1989-01-23 1990-01-22 Recombinant therapies for infection and hyperproliferative disorders

Publications (2)

Publication Number Publication Date
DE69032841D1 true DE69032841D1 (de) 1999-01-28
DE69032841T2 DE69032841T2 (de) 1999-05-12

Family

ID=26971882

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033975T Expired - Fee Related DE69033975T2 (de) 1989-01-23 1990-01-22 Rekombinanttherapien für Infektionen und hyperproliferative Störungen
DE69032841T Expired - Fee Related DE69032841T2 (de) 1989-01-23 1990-01-22 Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69033975T Expired - Fee Related DE69033975T2 (de) 1989-01-23 1990-01-22 Rekombinanttherapien für Infektionen und hyperproliferative Störungen

Country Status (5)

Country Link
US (2) US5861290A (de)
JP (1) JP2859252B2 (de)
AT (2) ATE174514T1 (de)
DE (2) DE69033975T2 (de)
PT (1) PT92931B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245560B1 (en) * 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
JPH08507687A (ja) * 1993-03-12 1996-08-20 クレイトン ユニバーシティ 遺伝子治療用の改良されたベクター
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US20030190753A1 (en) * 1995-11-09 2003-10-09 Nature Technology Corporation Vectors for gene transfer
EP0914163B1 (de) * 1997-02-28 2016-02-24 Enzo Therapeutics, Inc. Verfahren zur selektiven Immunherabregulation (SIDR)
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6545140B1 (en) * 1998-07-13 2003-04-08 University Of Georgia Research Foundation, Inc. DNA encoding an avian beta-defensin and uses thereof
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
DK1123086T3 (da) 1998-10-20 2010-06-14 Androclus Technologies S R L I Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6869936B1 (en) * 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
WO2002028165A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
PL371683A1 (en) * 2001-10-05 2005-06-27 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20040115254A1 (en) * 2002-09-06 2004-06-17 Genteric, Inc. Microcapsules and methods of use
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
WO2007020873A1 (ja) 2005-08-16 2007-02-22 Takara Bio Inc. 免疫不全ウイルス感染症の治療または予防のための核酸
EP1988923A1 (de) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Verfahren zur behandlung von unerwünschtem gewichtsverlust oder essstörungen durch verabreichung eines trkb-agonisten
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
WO2009037596A2 (en) 2007-09-17 2009-03-26 Barrick Gold Corporation Method to improve recovery of gold from double refractory gold ores
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
KR101293620B1 (ko) 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
EP0192658A4 (de) * 1984-07-30 1987-07-13 Salk Inst For Biological Studi Retrovirale gentransfervektoren.
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
EP0228458B2 (de) * 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
FR2606060B1 (fr) * 1986-10-31 1992-02-28 Wolf Philippe Dispositif d'injection sous pression dans un corps, notamment en bois, poreux, fissure ou presentant des cavites
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
EP0279582A3 (de) * 1987-02-17 1989-10-18 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
EP0293181B1 (de) * 1987-05-29 1995-08-16 Dana Farber Cancer Institute Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung
DE3876327D1 (de) * 1987-07-21 1993-01-14 Du Pont Merck Pharma Verfahren fuer die herstellung von in tierischen zellen stabilen und lebensfaehigen rekombinanten viralen vektoren.
US5306631A (en) * 1987-08-21 1994-04-26 University Of Colorado Foundation, Inc. Compositions and method for inhibition of HIV production
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
EP0378576B1 (de) * 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
DE3851153T2 (de) * 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
WO1989007150A1 (en) * 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
WO1990002806A1 (en) * 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
EP0361749B1 (de) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält
JP3140757B2 (ja) * 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
CA2425745C (en) * 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE4000286A1 (de) * 1990-01-08 1991-07-11 Bosch Gmbh Robert Abschirmbehaeltnis fuer einen bereich einer leiterplatte
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法

Also Published As

Publication number Publication date
US5837510A (en) 1998-11-17
ATE174514T1 (de) 1999-01-15
DE69033975D1 (de) 2002-08-01
DE69033975T2 (de) 2002-10-02
ATE219519T1 (de) 2002-07-15
DE69032841T2 (de) 1999-05-12
PT92931A (pt) 1990-07-31
JP2859252B2 (ja) 1999-02-17
US5861290A (en) 1999-01-19
PT92931B (pt) 1996-03-29
JPH10179181A (ja) 1998-07-07

Similar Documents

Publication Publication Date Title
DE69032841D1 (de) Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
ZA968382B (en) Vector and method of use for nucleic acid delivery to non-dividing cells
DE68915834D1 (de) Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
DE3381438D1 (de) Herstellung und expression struktureller gene.
DK309387A (da) Humant erythropoietin-gen samt expression deraf i transficerede celler
ATE41784T1 (de) Pflanzengen-expression.
ATE199741T1 (de) Gentherapeutische behandlung von tumoren mit einem endothelzellspezifischen, zellzyklusabhängigen wirkstoff
FR2712286B1 (fr) Nouveaux N-mercaptoalkyl alcanediamines et leur utilisation.
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
FI880383A0 (fi) Transformation och expression av en fraemmande gen i brassicaarter.
ATE73348T1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
ATE93272T1 (de) Expression von protein c.
ATE69241T1 (de) Herstellung von polypeptiden mit humangammainterferon-aktivitaet.
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
PT91702A (pt) Processo para a preparacao de novos nitratos organicos
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
BG50159A3 (en) Method for preparing derivatives of piranobenzadiasole
IL88371A0 (en) Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
ATE210184T1 (de) Ungespleisste varianten des gp350/220
EP0158317A3 (en) Biologic and method of preparing same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee